Small Pharmaceuticals
Market Cap
₹17,649 ₹17,649 Cr.
P/E
24.01
PEG
3.16
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Prevenar 20's vaccine ramp is the primary growth driver, contributing 45% of incremental revenue by FY31 amid a deliberate shift toward vaccines and specialty.

The bull case triggers on national adult immunization adoption and Prevenar 20 dominance, while the bear case hinges on NLEM expansion and Eliquis generic erosion.

Key Ratios

Debt to Equity
Debt to Equity
0.00
Div Yield (%)
Div Yield (%)
1.94
Individual < 2 lac
Individual < 2 lac
11.58 %
Institutions
Institutions
19.45 %
Market cap
Market cap
17,649 Cr
No. of Shareholders
No. of Shareholders
1.02 L
OPM (%)
OPM (%)
36.64 %
PE
PE
24.01
Prom Holding
Prom Holding
63.92 %
ROCE (%)
ROCE (%)
24.50
ROE (%)
ROE (%)
17.19
Sales
Sales
2,569 Cr
  • Pfizer
  • Eris Lifesciences
  • Alembic Pharma
  • TJI Pharma
Last updated on 29 Sep 2026
  • Pfizer sells vaccines, internal-medicine brands, hospital anti-infectives and inflammation medicines in India. About 96% of revenue comes from domestic sales.
  • Pfizer earlier carried low-growth primary-care brands alongside its core portfolio. Those brands moved to Cipla for exclusive marketing from December 2025.
  • Vaccines and hospital anti-infectives each bring about 20% of revenue and grow faster. Internal medicine brings about 45% of revenue.
  • Pfizer is shifting to premium vaccines and hospital anti-infectives. Its adult pneumococcal vaccine Prevenar 20 and its hospital anti-infective Emblaveo are now commercial.
  • Pfizer is debt-free with ₹3,110 Cr in cash. Payables exceed receivables.
  • Near-term profit depends on premium vaccines and hospital sales replacing legacy brands. Margins have recovered to about 33-35% after restructuring charges cleared.
  • Large tax and pricing disputes remain unresolved against small provisions. Cash covers an adverse outcome, but timing is uncertain.
  • CFO search before 8 Oct 2026
    the board names a successor to the outgoing finance chief. It sets interim cover.
  • Hypertension brand Minipress XL exit Q2FY27, by 14 Nov 2026
    the print shows the ~₹131 Cr lump sum from its US parent. It equals about 5% of FY26 revenue.
  • Major tax and pricing disputes no timeline
    about ₹600 Cr in tax demands stands against about ₹32 Cr provided. Drug-price demands add about ₹126 Cr.
  • Legacy brands under Cipla deal ongoing, no timeline
    the transfer removed field-force cost after a ₹41.73 Cr charge in FY26.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
3792
52W Range
High
5579
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

3 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

20 %
(as of Mar 24)
Antacid (Gelucil) - Market Share
0 %
(as of Jul 22)
Anti - Diabetes - Market Share
2.98 %
(as of Jul 22)
Anti-Infectives - Market Share
0.14 %
(as of May 19)
Anti-Malarial - Market Share
67 %
(as of Mar 24)
Anticholinergics ( Pacitane) - Market Share
2.34 %
(as of Nov 21)
Antineo Plastic - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)

    Peer Comparison

    Brands

    Autrin
    Becosules
    Corex Dx
    Gelusil
    Ovral L

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • Tata Communications Ltd.
    • Piramal Enterprises Ltd. - (Amalgamated)
    • Aarti Industries Ltd.
    • Suven Life Sciences Ltd.
    • AGI Greenpac Ltd.

    FAQs on Pfizer Ltd. Business

    Pfizer is engaged in manufacturing, marketing, distribution and trading of pharmaceutical products. The company has its own manufacturing facility. The company also has various independent contract / third party manufacturers based across the country. The company sells its products primarily in India through independent distributors.

    Pfizer major competitors are Eris Lifesciences, Natco Pharma, Alembic Pharma, Jubilant Pharmova, Caplin Point Labs., Astrazeneca Pharma, Marksans Pharma.
    Market Cap of Pfizer is ₹17,636 Crs.
    While the median market cap of its peers are ₹16,020 Crs.

    Pfizer seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Jun Sep Mar Jun Sep Mar Jun Jun Dec Mar Sep Mar Sep Dec Mar Jun Dec Sep
    Investor Presentation Mar Sep Mar Sep Dec
    Conference Call Jun Mar Mar Jun Sep Dec Dec Dec
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material